Related references
Note: Only part of the references are listed.Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study
Rashmi K. Murthy et al.
CANCER RESEARCH (2022)
Leptomeningeal metastatic cells adopt two phenotypic states
Jan Remsik et al.
CANCER REPORTS (2022)
Clinical trial of proton craniospinal irradiation for leptomeningeal metastases
T. Jonathan Yang et al.
NEURO-ONCOLOGY (2021)
Treatment strategies for breast cancer brain metastases
Caroline Bailleux et al.
BRITISH JOURNAL OF CANCER (2021)
Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors
Emilie Le Rhun et al.
NEURO-ONCOLOGY (2021)
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs
E. Felip et al.
ANNALS OF ONCOLOGY (2021)
OA09.02 Atezo-Brain: Single Arm Phase II Study of Atezolizumab Plus Chemotherapy in Stage IV NSCLC With Untreated Brain Metastases
E. Nadal et al.
Journal of Thoracic Oncology (2021)
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
Hussein A. Tawbi et al.
LANCET ONCOLOGY (2021)
CTNI-29. SAFETY AND FEASIBILITY OF RHENIUM-186 NANOLIPOSOME (186RNL) IN RECURRENT GLIOMA: THE RESPECT™ PHASE 1 TRIAL
Andrew Brenner et al.
NEURO-ONCOLOGY (2021)
Genomic comparison between cerebrospinal fluid and primary tumor revealed the genetic events associated with brain metastasis in lung adenocarcinoma
Zhiyong Deng et al.
CELL DEATH & DISEASE (2021)
Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases
Sanjay M. Prakadan et al.
NATURE COMMUNICATIONS (2021)
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
Priscilla K. Brastianos et al.
NATURE COMMUNICATIONS (2021)
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
Hope S. Rugo et al.
LANCET ONCOLOGY (2021)
Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases
Haruka Uezono et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2021)
Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: Results from the first stage of the phase II TUXEDO-1 trial
R. Bartsch et al.
ANNALS OF ONCOLOGY (2021)
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
L. A. Emens et al.
ANNALS OF ONCOLOGY (2021)
Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases
Inna Smalley et al.
CLINICAL CANCER RESEARCH (2021)
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
Keunchil Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.
Hamid Emamekhoo et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Clinical outcomes in patients (pts) with a history of central nervous system (CNS) metastases receiving talazoparib (TALA) or physician's choice of chemotherapy (PCT) in the phase 3 EMBRACA trial.
Jennifer Keating Litton et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer.
Erica Michelle Stringer-Reasor et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Cerebrospinal fluid diversion for leptomeningeal metastasis: palliative, procedural and oncologic outcomes
Evan D. Bander et al.
JOURNAL OF NEURO-ONCOLOGY (2021)
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
Jarushka Naidoo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
The Effect of Asymptomatic and/or Treated Brain Metastases on Efficacy of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis
Sihan Li et al.
FRONTIERS IN ONCOLOGY (2021)
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions
Emanuela Ferraro et al.
BREAST CANCER RESEARCH (2021)
Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations
Priscilla K. Brastianos et al.
NATURE CANCER (2021)
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program
Nikolaj Frost et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022
Rachel A. Freedman et al.
CLINICAL BREAST CANCER (2020)
Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series
Kourtney Holbrook et al.
CANCER (2020)
Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer
Emilie Le Rhun et al.
NEURO-ONCOLOGY (2020)
A retrospective, quantitative assessment of disease burden in patients with leptomeningeal metastases from non-small-cell lung cancer
Kathryn S. Nevel et al.
NEURO-ONCOLOGY (2020)
Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report
Zhaona Li et al.
THORACIC CANCER (2020)
ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases
Priya Kumthekar et al.
CLINICAL CANCER RESEARCH (2020)
Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance
Inna Smalley et al.
CLINICAL CANCER RESEARCH (2020)
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation?Positive Non?Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
James C. H. Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis
Myung-Ju Ahn et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
Robert H. Jones et al.
LANCET ONCOLOGY (2020)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
R. K. Murthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
Todd M. Bauer et al.
TARGETED ONCOLOGY (2020)
Single-center phase I/Ib study of concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD).
Isabella Claudia Glitza et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Nancy U. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC
Viola W. Zhu et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
Priscilla K. Brastianos et al.
NATURE MEDICINE (2020)
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paul K. Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
S. Park et al.
ANNALS OF ONCOLOGY (2020)
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial
F. Montemurro et al.
ANNALS OF ONCOLOGY (2020)
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer
Sara M. Tolaney et al.
CLINICAL CANCER RESEARCH (2020)
Craniospinal irradiation(CSI) in patients with leptomeningeal metastases: risk-benefit-profile and development of a prognostic score for decision making in the palliative setting
Michal Devecka et al.
BMC CANCER (2020)
Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression
Flora Zagouri et al.
CANCER TREATMENT REVIEWS (2020)
Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer
Rachna Malani et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer
Juergen Wolf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib
Felipe Batalini et al.
JCO PRECISION ONCOLOGY (2020)
Central Nervous System Cancers Version 3.2020
Louis Burt Nabors et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Long-term response to Olaparib in carcinomatous meningitis of a BRCA2 mutated ovarian cancer: A case report
Laure Favier et al.
MOLECULAR AND CLINICAL ONCOLOGY (2020)
Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis
Yudan Chi et al.
SCIENCE (2020)
Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy
Nicholas B. Figura et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases
Aki Morikawa et al.
CLINICAL CANCER RESEARCH (2019)
Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study
Ronan Flippot et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
A Comparison of Acute Toxicities Between Vertebral-Body-Sparing Proton Craniospinal Irradiation and Standard Photon CSI in Pediatric Patients
A. B. Hopper et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2-Metastatic Breast Cancer: Biological Mechanisms and New Treatments
Daniele Presti et al.
CANCERS (2019)
Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report
David Arias Ron et al.
FRONTIERS IN ONCOLOGY (2019)
Radiotherapy in Leptomeningeal Disease: A Systematic Review of Randomized and Non-randomized Trials
Samantha M. Buszek et al.
FRONTIERS IN ONCOLOGY (2019)
Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases
Elisabeth S. Bergen et al.
CLINICAL CANCER RESEARCH (2019)
Palliative Radiotherapy for Leptomeningeal Carcinomatosis-Analysis of Outcome, Prognostic Factors, and Symptom Response
Rami A. El Shafie et al.
FRONTIERS IN ONCOLOGY (2019)
Rapid regression of neurological symptoms in patients with metastasised ALK plus lung cancer who are treated with lorlatinib: a report of two cases
Huda Gafer et al.
BMJ CASE REPORTS (2019)
Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis
Pedro Exman et al.
NPJ BREAST CANCER (2019)
Leptomeningeal melanoma-A case series in the era of modern systemic therapy
Malmaruha Arasaratnam et al.
PIGMENT CELL & MELANOMA RESEARCH (2018)
Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy
Y. S. Li et al.
ANNALS OF ONCOLOGY (2018)
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review
Giuseppina Rosaria Rita Ricciardi et al.
BMC CANCER (2018)
Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer
Jia Jin et al.
BMC CANCER (2018)
Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
Georgina V. Long et al.
LANCET ONCOLOGY (2018)
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Angelo Di Leo et al.
LANCET ONCOLOGY (2018)
Intracerebral efficacy and tolerance of nivolumab in non small-cell lung cancer patients with brain metastases
Clement Gauvain et al.
LUNG CANCER (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The Utility of Liquid Biopsy in Central Nervous System Malignancies
Kathryn S. Nevel et al.
CURRENT ONCOLOGY REPORTS (2018)
Buparlisib is a brain penetrable pan-PI3K inhibitor
Mark C. de Gooijer et al.
SCIENTIFIC REPORTS (2018)
B7H3 As a Promoter of Metastasis and Promising Therapeutic Target
Peixin Dong et al.
FRONTIERS IN ONCOLOGY (2018)
Leukaemia hijacks a neural mechanism to invade the central nervous system
Hisayuki Yao et al.
NATURE (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis
Haixia Chen et al.
FRONTIERS IN PHARMACOLOGY (2018)
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J. Solomon et al.
LANCET ONCOLOGY (2018)
CMET-22. INTRATHECAL (IT) TRAZTUZUMAB (T) FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES (LM) IN PATIENTS (PTS) WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE (HER2+) CANCER: A MULTICENTER PHASE 1/2 STUDY
Priya Kumthekar et al.
NEURO-ONCOLOGY (2018)
Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2
Isabella C. Glitza et al.
ESMO OPEN (2018)
Brain Penetration of Lorlatinib and Cumulative Incidence Rates for CNS and Non CNS Progression from a Phase 1/2 Study
T. Bauer et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer
Shigeki Nanjo et al.
BRITISH JOURNAL OF CANCER (2018)
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy
B. Pistilli et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Rapid resolution of leptomeningeal disease with targeted therapy in a metastatic melanoma patient
Isabella C. Glitza et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases
Mengxi Ge et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
Alice T. Shaw et al.
LANCET ONCOLOGY (2017)
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A. Davies et al.
LANCET ONCOLOGY (2017)
Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study
Daniel N. Cagney et al.
NEURO-ONCOLOGY (2017)
Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors
Xuling Lin et al.
NEURO-ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours
E. Le Rhun et al.
ANNALS OF ONCOLOGY (2017)
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review
Michela Maur et al.
AMERICAN JOURNAL OF CASE REPORTS (2017)
Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis
Adrienne Boire et al.
CELL (2017)
Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature
Megan O. Jacus et al.
CLINICAL PHARMACOKINETICS (2016)
Phase II study of single agent buparlisib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
C. Grommes et al.
ANNALS OF ONCOLOGY (2016)
Endocrine Therapy for Leptomeningeal Metastases from ER-Positive Breast Cancer: Case Report and a Review of the Literature
Behyar Zoghi et al.
BREAST JOURNAL (2016)
MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis
Joanna H. Tong et al.
CLINICAL CANCER RESEARCH (2016)
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer
Shirish M. Gadgeel et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
Lucio Crino et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
Yang-Si Li et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Vemurafenib in leptomeningeal carcinomatosis from melanoma: a case report of near-complete response and prolonged survival
Charalampos S. Floudas et al.
MELANOMA RESEARCH (2016)
T-Lymphocytes Traffic into the Brain across the Blood-CSF Barrier: Evidence Using a Reconstituted Choroid Plexus Epithelium
Nathalie Strazielle et al.
PLOS ONE (2016)
Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
Madeleine Bangham et al.
GYNECOLOGIC ONCOLOGY REPORTS (2016)
Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report
Dae Won Kim et al.
BMC CANCER (2015)
A balanced view of the cerebrospinal fluid composition and functions: Focus on adult humans
Reynold Spector et al.
EXPERIMENTAL NEUROLOGY (2015)
Complete Cytologic Remission of V600E BRAF-Mutant Melanoma-Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib
Sofie Wilgenhof et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases
Daniel B. Costa et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma
Lilia Sakji-Dupre et al.
MELANOMA RESEARCH (2015)
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
Priscilla K. Brastianos et al.
CANCER DISCOVERY (2015)
A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer
David M. Jackman et al.
ONCOTARGET (2015)
Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report
Isabella C. Glitza et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA
I. E. Krop et al.
ANNALS OF ONCOLOGY (2015)
Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases
S. Gori et al.
ANNALS OF ONCOLOGY (2014)
All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer - A phase II study
Hanan Shawky et al.
JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE (2014)
Factors Influencing the CNS Distribution of a Novel MEK-1/2 Inhibitor: Implications for Combination Therapy for Melanoma Brain Metastases
Shruthi Vaidhyanathan et al.
DRUG METABOLISM AND DISPOSITION (2014)
Proton Beam Craniospinal Irradiation Reduces Acute Toxicity for Adults With Medulloblastoma
Aaron P. Brown et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Vemurafenib for Leptomeningeal Melanomatosis
Niklas Schaefer et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Investigation of the Effect of Active Efflux at the Blood-Brain Barrier on the Distribution of Nonsteroidal Aromatase Inhibitors in the Central Nervous System
Mari Miyajima et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer
Eunyoung Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
The Central Nervous System as a Sanctuary Site in ALK-Positive Non-Small-Cell Lung Cancer
Justin F. Gainor et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
Thomas Bachelot et al.
LANCET ONCOLOGY (2013)
Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report
Jee Min Lee et al.
MELANOMA RESEARCH (2013)
Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab
I. Bot et al.
JOURNAL OF NEUROLOGY (2012)
Rhenium-186 liposomes as convection-enhanced nanoparticle brachytherapy for treatment of glioblastoma
William T. Phillips et al.
NEURO-ONCOLOGY (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Malignant cells in cerebrospinal fluid (CSF): The meaning of a positive CSF cytology
J. P. Glass et al.
NEUROLOGY (2011)
Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT)
A. Niwinska et al.
ANNALS OF ONCOLOGY (2010)
Leptomeningeal metastases in the MRI era
J. L. Clarke et al.
NEUROLOGY (2010)
Pediatric medulloblastoma: Toxicity of current treatment and potential role of protontherapy
Piero Fossati et al.
CANCER TREATMENT REVIEWS (2009)
Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
Nancy U. Lin et al.
CLINICAL CANCER RESEARCH (2009)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma
Morris D. Groves et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer
Deann P. Atchley et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical features
Jeffrey J. Raizer et al.
NEURO-ONCOLOGY (2008)
A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies
Morris D. Groves et al.
NEURO-ONCOLOGY (2008)
Capecitabine therapy of central nervous system metastases from breast cancer
Meltem Ekenel et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: A case report
Yee-Lu Tham et al.
CLINICAL BREAST CANCER (2006)
The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study
W Boogerd et al.
EUROPEAN JOURNAL OF CANCER (2004)
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma
JC Bendell et al.
CANCER (2003)
Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection
M Ozdogan et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2003)
Response of leptomeningeal metastases from breast cancer to hormonal therapy
W Boogerd et al.
NEUROLOGY (2000)
Diagnostic evaluation of neurologic metastases
SA Jeyapalan et al.
CANCER INVESTIGATION (2000)
Share Paper
